Systemic administration of the checkpoint blockade antibody anti-CTLA4 results in severe autoimmune toxicity, limiting its clinical efficacy. Fransen and colleagues show here that peritumoral delivery of low doses of this immunomodulatory drug can trigger a systemic antitumor immune response while preventing the toxicity against other organs.
View details for DOI 10.1158/1078-0432.CCR-13-1923
View details for PubMedID 23965900
View details for PubMedCentralID PMC3817012